国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (1): 45-48.doi: 10.3760/cma.j.issn.1673-422X.2016.01.013

• 综述 • 上一篇    下一篇

非小细胞肺癌分子靶向治疗及其耐药

张钰,周建国,马虎   

  1. 563000 遵义医学院附属医院胸部肿瘤科
  • 收稿日期:2015-01-19 出版日期:2016-01-08 发布日期:2015-12-03
  • 通讯作者: 马虎 E-mail:mahuab@163.com
  • 基金资助:

    国家自然科学基金(81360351)

Molecular targeted therapy for non-small cell lung cancer and drug resistance

Zhang Yu, Zhou Jianguo, Ma Hu   

  1. Department of Chest Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China
  • Received:2015-01-19 Online:2016-01-08 Published:2015-12-03
  • Contact: Ma Hu E-mail:mahuab@163.com
  • Supported by:

    National Natural Science Foundation of China (81360351)

摘要: 以吉非替尼和厄洛替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌治疗中发挥重要作用,然而在临床前和临床研究中发现,许多患者对此类药物存在原发性耐药或获得性耐药,使其临床应用受到一定限制。目前许多研究致力于延缓、逆转耐药以及开发新的靶点,为非小细胞肺癌的靶向治疗提供了更多的可能。

关键词: 癌, 非小细胞肺, 突变, 受体, 表皮生长因子, 抗药性, 肿瘤, 分子靶向治疗

Abstract: Gefitinib and erlotinib play important roles, which as the representative of the epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). However, preclinical and clinical studies find that many patients exist primary or acquired drug resistance to this drug, which limits the use of molecular targeted therapy drugs. At present, there are many studies focus on delaying or reversing drug resistance and developing new targets, which provide more potential for the molecular targeted therapy of NSCLC.

Key words: Carcinoma, non-small-cell lung, Mutation, Receptor, epidermal growth factor, Drug resistance, neoplasm, Molecular targeted therapy